smartbax GmbH

smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team works on innovative solutions focusing on substances that simultaneously address several targets, thus hindering resistance development in bacteria. Moreover, the company specializes in the tailored activation of enzymatic pathways, as opposed to classical inhibition approaches. This is particularly promising in the context of difficult-to-treat biofilms. Knowing that preventing a resistance crisis tomorrow means taking action today, smartbax was founded in 2021 in Munich with the aim of making innovative research applicable in creating novel antibiotics that add true value for patients worldwide. smartbax is currently seed-funded by Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds and is aiming for Series A funding in the first half of 2024.